Anixa Biosciences Reports Positive Survival, Strong Safety in Lira-Cel Ovarian Cancer CAR-T Phase 1 Trial
ANIX sits 23% above its 52-week low of $2.44.
Summary
Anixa Biosciences announced updated positive survival observations from its ongoing Phase 1 trial of Lira-Cel, its CAR-T therapy for ovarian cancer. Crucially, the company also reported no dose-limiting toxicities, ICANS, or significant cytokine release syndrome (CRS) in the first three dose cohorts. For a small biotech company, these positive early-stage clinical results, particularly the strong safety profile, are highly material as they significantly de-risk the development of this novel therapy. This data provides a strong foundation for the program's future, suggesting both potential efficacy and good tolerability. Investors will closely monitor the continued progress of the Lira-Cel trial and anticipate further data readouts and potential advancement to later clinical stages.
At the time of this announcement, ANIX was trading at $2.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $100.6M. The 52-week trading range was $2.44 to $5.46. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.